Abstract

Retrospective Study

Impact of Intravenous Busulfan Pharmacokinetics on Safety in Pediatric Patients who have undergone Hematopoietic Stem Cell Transplant

Omar AL Mofleh*, Noha Awadalla, Amal AL Shafi, Lina Husain, Hanan AL Musabeh and Saad AL Daama

Published: 03 December, 2024 | Volume 7 - Issue 1 | Pages: 007-012

Introduction: Busulfan (Bu)-based regimens are crucial for myeloablative conditioning in pediatric allogeneic stem cell transplantation. Despite its efficacy, Intravenous Bu has a narrow therapeutic index and variable pharmacodynamics especially in children, heightening the risk of adverse events. This study explores Bu dosing and related organ toxicities in pediatric patients at a tertiary center in Saudi Arabia.
Methodology: This retrospective study at King Fahad Specialist Hospital in Dammam (KFSH-D), Saudi Arabia, included pediatric patients (≤16 years) treated with intravenous Bu before bone marrow transplantation from 2010 to 2022. Pharmacokinetic dose adjustments were based on AUC targets of 900-1350 µMol-min. Descriptive measures included mean, Standard Deviation (SD), median, minimum-maximum values, counts, and percentages. Statistical analyses used Kruskal-Wallis, Chi-square, and Fisher’s exact tests. Ethical approval was obtained from KFSH-D.
Results: We identified 44 pediatric patients who underwent Bu prior to HSCT. Mean age was 4.95 ± 2.49 years, with a female majority (56.8%). Primary diseases included Beta Thalassemia (34.09%), Neuroblastoma (29.55%) among others. There was no significant difference in the cohort’s demographic and clinical features of the cohort. Nonetheless, higher infections were found in the Low-AUC group (66.7%) compared to the Target-AUC (40.0%) and Higher-AUC groups (0.0%) (p = 0.015).
Conclusion: This study emphasizes the need for therapeutic drug monitoring and individualized Bu dosing in pediatric HSCT to minimize toxicity and improve outcomes. Larger multicenter studies are recommended to refine dosing strategies and enhance the safety and efficacy of Bu-based regimens.

Read Full Article HTML DOI: 10.29328/journal.ijbmr.1001018 Cite this Article Read Full Article PDF

Keywords:

Busulfan; Pediatrics; Adverse events; AUC; Toxicity; HSCT; Drug monitoring

References

  1. Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, et al. Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. Int J Hematol. 2021;113(1):128-133. Available from: https://doi.org/10.1007/s12185-020-02990-y
  2. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344-353. Available from: https://doi.org/10.1182/blood-2014-02-514778
  3. Masson E, Zamboni WC. Pharmacokinetic Optimisation of Cancer Chemotherapy. Clin Pharmacokinet. 1997;32(4):324-343. Available from: https://doi.org/10.2165/00003088-199732040-00005
  4. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant. 2001;27(11):1121-4. Available from: https://doi.org/10.1038/sj.bmt.1703047
  5. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28(8):743-51. Available from: https://doi.org/10.1038/sj.bmt.1703207
  6. Vassal G. Busulfan and Veno-occlusive Disease of the Liver. Ann Intern Med. 1990;112(11):881. Available from: https://doi.org/10.7326/0003-4819-112-11-881_1
  7. Tsakiris DA, Tichelli A. Thrombotic complications after haematopoietic stem cell transplantation: early and late effects. Best Pract Res Clin Haematol. 2009;22(1):137-145. Available from: https://doi.org/10.1016/j.beha.2008.12.002
  8. Hassan Z, Nilsson C, Hassan M. Liposomal busulphan: bioavailability and effect on bone marrow in mice. Bone Marrow Transplant. 1998;22(9):913-918. Available from: https://doi.org/10.1038/sj.bmt.1701458
  9. Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8(3):145-54. Available from: https://doi.org/10.1053/bbmt.2002.v8.pm11939604
  10. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8(9):493-500. Available from: https://doi.org/10.1053/bbmt.2002.v8.pm12374454
  11. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children. N Engl J Med. 2003;349(12):1157-1167. Available from: https://doi.org/10.1056/nejmra035092
  12. Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, et al. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017;13(9):901-923. Available from: https://doi.org/10.1080/17425255.2017.1360277
  13. Nava T, Kassir N, Rezgui MA, Uppugunduri CRS, Huezo-Diaz Curtis P, Duval M, et al. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2018;84(7):1494-1504. Available from: https://doi.org/10.1111/bcp.13566
  14. Kim MG, Kwak A, Choi B, Ji E, Oh JM, Kim K. Effect of glutathione S‐transferase genetic polymorphisms on busulfan pharmacokinetics and veno‐occlusive disease in hematopoietic stem cell transplantation: A meta‐ Basic Clin Pharmacol Toxicol. 2019;124(6):691-703. Available from: https://doi.org/10.1111/bcpt.13185
  15. Ansari M, Huezo-Diaz P, Rezgui MA, Marktel S, Duval M, Bittencourt H, et al. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. Bone Marrow Transplant. 2016;51(3):377-383. Available from: https://doi.org/10.1038/bmt.2015.321
  16. Hassan Z, Hellström-Lindberg E, Alsadi S, Edgren M, Hägglund H, Hassan M. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplant. 2002;30(3):141-147. Available from: https://doi.org/10.1038/sj.bmt.1703615
  17. DeLeve LD, Wang X. Role of Oxidative Stress and Glutathione in Busulfan Toxicity in Cultured Murine Hepatocytes. Pharmacology. 2000;60(3):143-154. Available from: https://doi.org/10.1159/000028359
  18. Feng X, Wu Y, Zhang J, Li J, Zhu G, Fan D, et al. Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis. BMC Pediatr. 2020;20(1):176. Available from: https://doi.org/10.1186/s12887-020-02028-6
  19. Warsy AS, Al-Jaser MH, Albdass A, Al-Daihan S, Alanazi M. Is consanguinity prevalence decreasing in Saudis?: A study in two generations. Afr Health Sci. 2014;14(2):314-321. Available from: https://doi.org/10.4314/ahs.v14i2.5
  20. Albanghali MA. Prevalence of Consanguineous Marriage among Saudi Citizens of Albaha, a Cross-Sectional Study. Int J Environ Res Public Health. 2023;20(4):3767. Available from: https://doi.org/10.3390/ijerph20043767
  21. Alhajori FS, Makkawi MH, Alasmari SZ, Shaikh AA, Baig MA. Estimating the prevalence of pediatric hematological malignancies in Al-Madinah Al-Munawwarah, Saudi Arabia. Saudi Med J. 2023;44(5):504-508. Available from: https://doi.org/10.15537/smj.2023.44.5.20220915
  22. Chaudhri E, Fathi W, Hussain F, Hashmi SK. The Increasing Trends in Cases of the Most Common Cancers in Saudi Arabia. J Epidemiol Glob Health. 2020;10(4):258-262. Available from: https://doi.org/10.2991/jegh.k.200515.001
  23. el-Hazmi MA, al-Swailem AR, Warsy AS, al-Swailem AM, Sulaimani R, al-Meshari AA. Consanguinity among the Saudi Arabian population. J Med Genet. 1995;32(8):623-626. Available from: https://doi.org/10.1136/jmg.32.8.623
  24. Hill BT. It’s Personal: Achieving Optimal Busulfan Exposure for All Patients. Biol Blood Marrow Transplant. 2016;22(7):1149-1150. Available from: https://doi.org/10.1016/j.bbmt.2016.04.024
  25. Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, et al. Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software. Ther Drug Monit. 2016;38(3):332-342. Available from: https://doi.org/10.1097/ftd.0000000000000276
  26. Bartelink IH, Bredius RGM, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, et al. Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2009;15(2):231-241. Available from: https://doi.org/10.1016/j.bbmt.2008.11.022
  27. Zhou S, Zhai Y, Yan L, Shi X, Shang J, Wu D, et al. Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment. J Clin Med. 2023;12(19):6239. Available from: https://doi.org/10.3390/jcm12196239
  28. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963-6970. Available from: https://doi.org/10.1182/blood-2011-01-332007
  29. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375-6382. Available from: https://doi.org/10.1182/blood-2011-01-329821
  30. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, et al. Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol. 2015;33(6):540-549. Available from: https://doi.org/10.1200/jco.2014.56.2025
  31. Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4(6):e293-e301. Available from: https://doi.org/10.1016/s2352-3026(17)30081-9
  32. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation. Biol Blood Marrow Transplant. 2006;12(5):560-565. Available from: https://doi.org/10.1016/j.bbmt.2005.12.034

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?